10-Q: Liminatus Pharma Faces Going Concern Doubt Amid Q3 Losses

Liminatus Pharma, a pre-clinical biopharmaceutical company, reported significant losses and a going concern warning in its Q3 2025 filing, despite a recent business combination and capital raise.

Summary

• Reported a net loss of $(1,823,351) for the three months ended September 30, 2025, a significant increase from $(601,372) in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $(2,037,590), an improvement from $(3,316,557) in the same period of 2024, primarily due to the forgiveness of unrelated vendor payables.
• Management has concluded there is "substantial doubt about its ability to continue as a going concern" for one year after the filing date.
• Cash balance increased to $724,502 as of September 30, 2025, from $56,319 at December 31, 2024, largely due to proceeds from the PIPE Financing.
• Research and development expenses decreased to $0 for both the three and nine months ended September 30, 2025, following the termination of license agreements with TDT in August 2024.
• General and administrative expenses significantly increased by $515,089 (277%) for the three months and $1,606,059 (336%) for the nine months ended September 30, 2025, primarily due to costs associated with operating as a publicly traded company and the Business Combination.
• The company completed a Business Combination with Iris Acquisition Corp. on April 30, 2025, and subsequently listed on Nasdaq.
• A $15,000,000 PIPE Financing was completed as part of the Business Combination, including $10,556,500 in cash proceeds.
• Converted $14,797,901 of related party debt and accrued interest into common stock during the Business Combination.
• Identified material weaknesses in internal control over financial reporting related to a lack of formalized control environment and inadequate segregation of duties.

Sentiment

Score: 2

Explanation: The company faces significant financial challenges, explicitly stating "substantial doubt about its ability to continue as a going concern." This, combined with increased quarterly losses, negative operating cash flow, and material weaknesses in internal controls, indicates a highly precarious financial position. While a recent capital raise provided some liquidity, the long-term viability is highly uncertain without further successful financing and product development.

Positives

• Cash balance significantly increased to $724,502 as of September 30, 2025, from $56,319 at December 31, 2024.
• Net loss for the nine months ended September 30, 2025, improved to $(2,037,590) from $(3,316,557) in the prior year, largely due to a $2,142,297 gain from the forgiveness of unrelated vendor payables.
• Successful completion of the Business Combination with Iris Acquisition Corp. and listing on Nasdaq on May 1, 2025.
• Secured $15,000,000 through a PIPE Financing, including $10,556,500 in cash proceeds.
• Termination of CAR-T and Vaccine license agreements with TDT resulted in the forgiveness of $2,142,297 in payables, recorded as a gain.
• The company holds an exclusive license for CD47 immune checkpoint inhibitor products (IBA101) to treat solid cancers, with no current license fees or milestone payments owed.

Negatives

• Management has concluded there is "substantial doubt about its ability to continue as a going concern" for one year after the filing date.
• Reported a higher net loss of $(1,823,351) for the three months ended September 30, 2025, compared to $(601,372) for the same period in 2024.
• Operating expenses increased by 29% for the three months ended September 30, 2025, primarily due to higher general and administrative costs associated with being a public company.
• Incurred a $1,740,000 loss on the exchange of common stock for warrants on July 16, 2025.
• All outstanding related party debt agreements, totaling $1,442,500 as of September 30, 2025, are past due, although repayment has been mutually deferred.
• A $500,000 deferred underwriting fee became due on October 27, 2025, and remains unpaid.
• The company is a pre-clinical stage biopharmaceutical company with no revenue generated to date and expects to incur significant operating losses for the foreseeable future.
• Identified material weaknesses in internal control over financial reporting, including a lack of formalized control environment and inadequate segregation of duties.

Risks

• Substantial doubt about the company's ability to continue as a going concern for one year after the financial statements are issued.
• Inability to raise adequate additional capital through equity or debt financings on acceptable terms, which would require reevaluation of future operations.
• Potential dilution of existing members if additional equity is sold, and newly issued equity securities may contain senior rights and preferences.
• Issued debt securities may contain covenants limiting the company's ability to pay dividends or make other distributions to stockholders.
• Uncertainty regarding whether the company's intellectual property (IBA101) will develop into successful commercial products.
• Material weaknesses in internal control over financial reporting, specifically a lack of formalized control environment and inadequate segregation of duties, which could lead to material misstatements.
• Reliance on related parties for debt financing, with all current related party loans being past due, even if repayment is mutually deferred.
• The company is a pre-clinical stage biopharmaceutical company, inherently facing high risks associated with drug development, clinical trials, and regulatory approvals.

Future Outlook

Management's plans to address the going concern issue include raising additional cash through equity and debt financings or other arrangements. The company's ability to generate future revenue depends entirely on the successful development and commercialization of its intellectual property, specifically its IBA101 candidate. There is no assurance that adequate capital can be raised on acceptable terms, and failure to do so would require a reevaluation of future operations.

Management Comments

• "Management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued."
• "Management's plans relating to the above include raising additional cash through equity and debt financings or other arrangements to fund operations."
• "There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all."
• "The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock."
• "Issued debt securities may contain covenants and limit the Company's ability to pay dividends or make other distributions to stockholders."
• "If the Company is unable to obtain such additional financing, future operations would need to be reevaluated."

Industry Context

Liminatus Pharma operates in the highly speculative and capital-intensive pre-clinical biopharmaceutical sector. The development of novel immune-modulating cancer therapies, such as anti-CD47 monoclonal antibodies, is a competitive field with high potential but also significant risks and long development timelines. The termination of previous CAR-T and Vaccine licenses and the focus on IBA101 indicate a strategic pivot or streamlining of its pipeline. The "going concern" warning is common for early-stage biotech companies that have not yet commercialized products and rely heavily on external financing.

Comparison to Industry Standards

• Pre-clinical stage biopharmaceutical companies typically incur significant operating losses and negative cash flows as they invest heavily in research and development without generating product revenue. Liminatus Pharma's current financial state, including its accumulated deficit and reliance on financing, aligns with this industry characteristic.
• The "going concern" warning is a frequent disclosure for early-stage biotech firms, such as many small-cap oncology developers, that are years away from potential commercialization and depend on successful clinical trials and subsequent funding rounds. For example, companies like OncoSec Medical Inc. or Checkpoint Therapeutics, Inc. have faced similar liquidity challenges at various stages of their development.
• The cessation of R&D expenses due to license terminations is unusual and suggests a significant shift in strategy or a failure of previous programs, which could be a red flag compared to peers actively advancing multiple pipeline candidates.
• The substantial increase in general and administrative expenses post-Business Combination is typical for companies transitioning to public status, as they incur new costs related to compliance, legal, and accounting for public reporting.

Corporate Governance

Related Party Transactions

• Extensive related party debt from Feelux Co., Ltd., Car-Tcellkor, Valetudo Therapeutics LLC, Ewon Comfortech Co., Ltd., Prophase Sciences LLC, and Hana Immunotherapeutics, LLC.
• A significant portion of this related party debt ($14,797,901) was converted into common stock during the Business Combination.
• Remaining related party debt of $1,442,500 as of September 30, 2025, is past due but repayment has been mutually deferred.
• Owed $180,253 to the CEO for compensation under his employment agreement.
• Due $126,275 from Viral Gene, Inc., where the company's CEO is also the CEO, for a loan and expenses paid on its behalf.
• The PIPE Financing included $3,427,000 funded indirectly by the PIPE investor through promissory notes between Prophase Sciences, LLC (a related party) and Liminatus, which were converted into shares.
• The non-cash component of the PIPE Financing included the conversion of $4,443,500 in amounts borrowed from a consortium of related parties, which were used to fund an unsecured promissory note between Liminatus and Iris.

Stakeholder Impact

• Shareholders: Face significant dilution risk from potential future equity raises. Existing common stock holders may have their rights subordinated if preferred stock is issued. The "going concern" warning indicates high risk to investment value.
• Employees: The company's financial instability and "going concern" warning could create job insecurity.
• Creditors (Related Parties): While repayment of past-due loans is mutually deferred, the company's financial health impacts the recoverability of these debts.
• Customers (Future): As a pre-clinical company, there are no current customers. Future customers depend on successful product development and commercialization, which is highly uncertain.
• Suppliers/Vendors: The company's liquidity issues and unpaid underwriting fees could impact relationships with vendors.

Next Steps

• Raise additional cash through equity and debt financings or other arrangements to fund operations.
• Reevaluate future operations if unable to obtain additional financing.
• Design formal written policies and procedures regarding internal controls over financial reporting.
• Increase communication with personnel and third-party professionals regarding complex accounting applications.
• Evaluate the need for additional qualified personnel to address internal control weaknesses.
• Continue development of IBA101, its humanized anti CD47 monoclonal antibody candidate.

Key Dates

Recommendation

The filing presents a dire financial situation, explicitly stating "substantial doubt about its ability to continue as a going concern." This is the most critical red flag for any investor. While the company completed a business combination and PIPE financing, it continues to incur significant losses, has negative operating cash flow, and has identified material weaknesses in internal controls. The R&D pipeline is limited to a single pre-clinical candidate (IBA101) after terminating other licenses, and the path to commercialization is long, uncertain, and capital-intensive. The reliance on related party debt, even if deferred, highlights underlying financial strain. The combination of severe liquidity concerns, ongoing losses, internal control issues, and the early stage of its sole pipeline asset makes this a high-risk investment with a very low probability of success in the near to medium term. Investors should consider exiting their positions.

Keywords

Biopharmaceutical, Cancer Therapy, CD47, IBA101, Pre-clinical, SEC Filing, 10-Q, Going Concern, Nasdaq, Business Combination, PIPE Financing, Warrants, Internal Controls, Drug Development, Oncology